It's too early to know this since no clinical trials have been started yet. I've learned the hard way that entering biotech too early is usually a mistake.
Please correct me if I'm wrong and they've at least done a phase I safety trial in another country. I've not had time to do the research and it appears you may have done so.
Thanks...
In Reply to 'hedgeclipper' IMO a buying opportunity. All the fundamentals still there for CohBar to be the next (and best) NASH play.